Corrigendum to Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes. Am J Ophthalmol 2022;234:223-234.
Titel:
Corrigendum to Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes. Am J Ophthalmol 2022;234:223-234.
Auteur:
Beykin, Gala Stell, Laurel Halim, Muhammad Sohail Nuñez, Mariana Popova, Lilia Nguyen, Bac T. Groth, Sylvia L. Dennis, Amy Li, Zhongqiu Atkins, Melissa Khavari, Tom Wang, Sophia Y. Chang, Robert Fisher, Ann C. Sepah, Yasir J. Goldberg, Jeffrey L.